These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 6427831)

  • 41. Effects of chronic dietary lithium on behavioral indices of dopamine denervation supersensitivity in the rat.
    Swerdlow NR; Lee D; Koob GF; Vaccarino FJ
    J Pharmacol Exp Ther; 1985 Nov; 235(2):324-9. PubMed ID: 3932641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat.
    Rupniak NM; Mann S; Hall MD; Fleminger S; Kilpatrick G; Jenner P; Marsden CD
    Psychopharmacology (Berl); 1984; 84(4):503-11. PubMed ID: 6441951
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term d-amphetamine in rats: lack of change in post-synaptic dopamine receptor sensitivity.
    Jackson DM; Bailey RC; Christie MJ; Crisp CA; Skerritt JH
    Psychopharmacology (Berl); 1981; 73(3):276-80. PubMed ID: 6787649
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Are the catecholestrogens involved in estrogen-induced striatal dopamine receptor supersensitivity?
    Ferretti C; Ghi P; Blengio M; Gaietta G; Barrera G; Genazzani E
    Eur J Pharmacol; 1989 Jul; 166(2):149-56. PubMed ID: 2551698
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined.
    Rastogi SK; Rastogi RB; Singhal RL; Lapierre YD
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(2-3):153-64. PubMed ID: 6137027
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential liabilities of haloperidol and thioridazine for inducing apomorphine hypersensitivity.
    De Veaugh-Geiss J; Devanand DP; Carey RJ
    Biol Psychiatry; 1982 Nov; 17(11):1289-301. PubMed ID: 6891268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dopaminergic alterations in cotreatments attenuating haloperidol-induced hypersensitivity.
    Carvey PM; Kao LC; Zhang TJ; Amdur RL; Lin DH; Singh R; Klawans HL
    Pharmacol Biochem Behav; 1990 Feb; 35(2):291-300. PubMed ID: 2320636
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of buspirone on dopaminergic supersensitivity.
    Queiroz CM; Frussa-Filho R
    Life Sci; 1997; 61(4):371-82. PubMed ID: 9244363
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions.
    Ogren SO; Hall H; Köhler C; Magnusson O; Sjöstrand SE
    Psychopharmacology (Berl); 1986; 90(3):287-94. PubMed ID: 2947255
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modulating role of lithium on dopamine turnover, prolactin release, and behavioral supersensitivity following haloperidol and reserpine.
    McIntyre IM; Kuhn C; Demitriou S; Fucek FR; Stanley M
    Psychopharmacology (Berl); 1983; 81(2):150-4. PubMed ID: 6415746
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum.
    Allen RM; Lane JD; Brauchi JT
    Eur J Pharmacol; 1980 Jul; 65(2-3):313-5. PubMed ID: 7190503
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Electroconvulsive treatment and haloperidol: effects on pre- and postsynaptic dopamine receptors in rat brain.
    Reches A; Wagner HR; Barkai AI; Jackson V; Yablonskaya-Alter E; Fahn S
    Psychopharmacology (Berl); 1984; 83(2):155-8. PubMed ID: 6431465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of treatment and withdrawal from chronic lithium in rats on stimulant-induced responses.
    Lerer B; Globus M; Brik E; Hamburger R; Belmaker RH
    Neuropsychobiology; 1984; 11(1):28-32. PubMed ID: 6738831
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Definition of the in-vivo accumulation of [3H]spiperone in brain using haloperidol and sulpiride to determine functional dopamine receptor occupation.
    Chivers JK; Reavill C; Jenner P; Marsden CD
    J Pharm Pharmacol; 1988 Sep; 40(9):613-9. PubMed ID: 2907027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of naloxone on d-amphetamine- and apomorphine-induced behavior.
    Hitzemann R; Curell J; Hom D; Loh H
    Neuropharmacology; 1982 Oct; 21(10):1005-11. PubMed ID: 6890635
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
    Bhargava HN
    Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antagonizing effect of lithium on the development of dopamine supersensitivity in the tuberoinfundibular system.
    Tanimoto K; Maeda K; Chihara K
    Brain Res; 1982 Aug; 245(1):163-6. PubMed ID: 6811103
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
    Gordon JH; Diamond BI
    Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential alteration in striatal dopaminergic and cortical serotonergic receptors induced by repeated administration of haloperidol or centbutindole in rats.
    Gulati A; Srimal RC; Dhawan BN
    Pharmacology; 1988; 36(6):396-404. PubMed ID: 2901759
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity.
    Creese I; Burt DR; Snyder SH
    Science; 1977 Aug; 197(4303):596-8. PubMed ID: 877576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.